Free Trial

Q32 Bio (QTTB) Competitors

Q32 Bio logo
$1.45 -0.10 (-6.45%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.58 +0.13 (+8.62%)
As of 06/27/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QTTB vs. SRZN, JMAC, PDSB, XBIT, IZTC, IMUX, OCX, PYXS, SNTI, and STRO

Should you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Surrozen (SRZN), Maxpro Capital Acquisition (JMAC), PDS Biotechnology (PDSB), XBiotech (XBIT), Invizyne Technologies (IZTC), Immunic (IMUX), OncoCyte (OCX), Pyxis Oncology (PYXS), Senti Biosciences (SNTI), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry.

Q32 Bio vs. Its Competitors

Surrozen (NASDAQ:SRZN) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Surrozen and Surrozen both had 2 articles in the media. Surrozen's average media sentiment score of 1.31 beat Q32 Bio's score of 0.94 indicating that Surrozen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Surrozen
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Q32 Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Surrozen has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500.

Q32 Bio has lower revenue, but higher earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surrozen$10.65M7.25-$63.56M-$24.96-0.36
Q32 Bio$1.16M15.25-$47.73M-$4.94-0.29

Q32 Bio's return on equity of -447.33% beat Surrozen's return on equity.

Company Net Margins Return on Equity Return on Assets
SurrozenN/A -842.90% -71.32%
Q32 Bio N/A -447.33%-59.77%

Surrozen presently has a consensus price target of $38.50, suggesting a potential upside of 326.83%. Q32 Bio has a consensus price target of $12.17, suggesting a potential upside of 739.08%. Given Q32 Bio's higher probable upside, analysts clearly believe Q32 Bio is more favorable than Surrozen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surrozen
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Q32 Bio
0 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

66.6% of Surrozen shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 45.2% of Surrozen shares are held by insiders. Comparatively, 40.0% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Q32 Bio beats Surrozen on 7 of the 13 factors compared between the two stocks.

Get Q32 Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QTTB vs. The Competition

MetricQ32 BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$18.91M$2.84B$5.48B$8.87B
Dividend YieldN/A2.70%5.35%4.15%
P/E Ratio-0.2921.1626.1119.66
Price / Sales15.25282.55386.66105.07
Price / CashN/A43.1436.4056.81
Price / Book3.097.207.905.44
Net Income-$47.73M-$55.15M$3.15B$249.37M
7 Day Performance-6.45%0.76%3.07%3.94%
1 Month Performance-20.77%6.31%6.01%5.26%
1 Year Performance-91.92%-0.21%32.05%17.07%

Q32 Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QTTB
Q32 Bio
2.779 of 5 stars
$1.45
-6.5%
$12.17
+739.1%
-90.5%$18.91M$1.16M-0.2939Analyst Upgrade
High Trading Volume
SRZN
Surrozen
3.1731 of 5 stars
$9.54
+0.6%
$38.50
+303.6%
-9.3%$81.69M$11.64M-0.3880
JMAC
Maxpro Capital Acquisition
N/A$6.07
-12.2%
N/A+3,137.3%$81.55MN/A0.002,021Gap Up
PDSB
PDS Biotechnology
2.182 of 5 stars
$1.78
+1.7%
$9.00
+405.6%
-53.2%$81.36MN/A-1.5320
XBIT
XBiotech
0.6271 of 5 stars
$2.74
+3.8%
N/A-39.3%$80.49M$4.01M-2.54100News Coverage
Positive News
IZTC
Invizyne Technologies
N/A$12.81
-2.6%
N/AN/A$80.09MN/A0.0029
IMUX
Immunic
2.6966 of 5 stars
$0.82
+1.9%
$11.60
+1,313.8%
-31.4%$78.62MN/A-0.6770Analyst Forecast
OCX
OncoCyte
2.7532 of 5 stars
$2.73
+3.0%
$6.06
+122.1%
+8.7%$78.08M$3.84M-0.77120Positive News
Gap Up
PYXS
Pyxis Oncology
2.0459 of 5 stars
$1.21
+0.8%
$9.00
+643.8%
-65.7%$74.96M$16.15M-1.1760
SNTI
Senti Biosciences
2.6958 of 5 stars
$2.86
+10.0%
$8.50
+197.2%
-32.3%$74.59M$2.56M-0.184Gap Down
STRO
Sutro Biopharma
3.7143 of 5 stars
$0.88
+10.2%
$6.11
+594.3%
-74.9%$74.38M$66.43M-0.55240Positive News

Related Companies and Tools


This page (NASDAQ:QTTB) was last updated on 6/28/2025 by MarketBeat.com Staff
From Our Partners